sinc
emerg
middl
east
respiratori
syndrom
mer
affect
countri
global
total
laboratoryconfirm
case
fatal
rate
similar
sever
acut
respiratori
syndrom
sar
mer
also
caus
coronaviru
cov
name
merscov
unlik
sar
epidem
rapidli
die
intermedi
amplif
anim
host
segreg
human
closur
wild
anim
market
southern
china
mer
epidem
persist
two
year
sign
abat
persist
epidem
may
partli
due
difficulti
control
contact
peopl
dromedari
camel
major
zoonot
sourc
sinc
still
effect
antivir
agent
treatment
merscov
infect
rapid
accur
laboratori
diagnosi
essenti
commenc
infect
control
measur
although
merscov
cultur
antibodi
detect
method
avail
laboratori
diagnosi
human
merscov
infect
mainli
achiev
quantit
realtim
rtpcr
use
rnadepend
rna
polymeras
region
upstream
envelop
gene
nucleocapsid
gene
merscov
howev
cost
quantit
realtim
rtpcr
still
high
expertis
may
avail
particularli
clinic
microbiolog
laboratori
middl
east
case
identifi
enzymelink
immunosorb
assay
elisa
antigen
detect
offer
inexpens
userfriendli
way
laboratori
diagnosi
respiratori
viral
infect
includ
mer
antigen
detect
elisa
use
laboratori
diagnosi
patient
suspect
mer
also
field
studi
dromedari
well
suspect
anim
reservoir
far
antigen
detect
assay
avail
merscov
articl
report
develop
evalu
monoclon
antibodi
mab
base
captur
elisa
merscov
nucleocapsid
protein
np
detect
clinic
isol
merscov
kindli
provid
ra
fouchier
work
infecti
merscov
perform
insid
biosafeti
cabinet
standard
oper
procedur
approv
biosafeti
viral
cultur
rna
extract
perform
describ
produc
plasmid
protein
purif
primer
ttc
atg
gca
tcc
cct
gct
gca
gac
atc
agt
gtt
aac
atc
aat
use
amplifi
gene
encod
np
merscov
rtpcr
sequenc
code
amino
acid
residu
np
amplifi
clone
ecori
sali
site
express
vector
novagen
merck
millipor
billerica
usa
frame
upstream
seri
six
histidin
residu
rnp
protein
express
escherichia
coli
cell
invitrogen
life
technolog
grand
island
ny
usa
purifi
use
ninta
affin
chromatograph
column
novagen
merck
millipor
billerica
usa
accord
manufactur
instruct
antimerscovrnp
mab
produc
use
protocol
describ
briefli
sixweekold
femal
balbc
mice
immun
purifi
merscovrnp
emulsifi
equal
volum
freund
complet
adjuv
sigmaaldrich
saint
loui
mo
usa
subcutan
two
booster
immun
use
antigen
emulsifi
incomplet
freund
adjuv
carri
day
blood
sampl
obtain
tail
vein
immun
mice
test
titer
purifi
merscovrnp
elisa
merscovrnpco
micropl
final
booster
dose
spleen
mice
remov
splenocyt
fuse
mous
myeloma
cell
line
cultur
supernat
individu
hybridoma
clone
screen
purifi
merscovrnp
elisa
subclon
three
time
limit
dilut
stabl
hybridoma
cell
inject
abdomin
caviti
mous
produc
ascit
fluid
mab
purifi
first
precipit
ammonium
sulfat
diethylaminoethyl
column
high
perform
liquid
chromatographi
concentr
purifi
igg
determin
absorb
anim
procedur
approv
offici
xiamen
univers
institut
committe
use
care
laboratori
anim
western
blot
analysi
perform
accord
publish
briefli
purifi
rnp
merscov
human
cov
hcov
respect
subject
sdspage
transfer
nitrocellulos
membran
ge
healthcar
littl
chalfont
buckinghamshir
uk
membran
block
skim
milk
trisbuff
salin
incub
mous
antimerscovrnp
immun
sera
min
interact
detect
dilut
horseradish
peroxidas
hrp
conjug
goat
antimous
igg
novex
life
technolog
grand
island
ny
usa
visual
tmb
liquid
substrat
system
membran
sigma
aldrich
saint
loui
mo
usa
captur
elisa
merscovnp
detect
develop
describ
previous
minor
micropl
sigma
aldrich
saint
loui
mo
usa
precoat
first
antimerscovrnp
mab
incub
overnight
block
reagent
phosphatebuff
salin
sucros
caseinna
gelatin
inactiv
merscov
two
influenza
viru
strain
one
influenza
viru
b
strain
one
respiratori
syncyti
viru
rsv
strain
purifi
rnp
merscov
dilut
phosphatebuff
salin
skim
milk
inactiv
viral
lysat
dilut
viru
titer
serial
dilut
specif
viral
lysi
buffer
ad
coat
well
sampl
fix
concentr
purifi
np
viral
cell
cultur
lysat
ad
well
duplic
plate
shaken
min
incub
min
well
wash
five
time
second
antimerscovrnp
mab
conjug
hrp
ad
plate
incub
min
five
wash
detect
carri
ad
tmb
per
well
incub
min
follow
addit
od
nm
measur
micropl
reader
cutoff
valu
set
mean
valu
human
nasopharyng
aspir
npa
neg
influenza
b
c
virus
adenoviru
rsv
parainfluenza
virus
human
rhinovirus
human
metapneumoviru
merscov
npa
patient
viral
respiratori
tract
infect
influenza
viru
n
influenza
b
viru
n
influenza
c
viru
n
adenoviru
n
rsv
n
parainfluenza
viru
n
parainfluenza
viru
n
parainfluenza
viru
n
parainfluenza
viru
n
human
rhinovirus
n
human
metapneumoviru
n
n
n
n
n
simul
merscov
posit
npa
use
evalu
elisa
npa
posit
influenza
c
viru
parainfluenza
viru
human
rhinovirus
human
metapneumoviru
hcov
determin
rtpcr
respiratori
virus
determin
indirect
immunofluoresc
assay
describ
previou
merscov
cultur
titrat
perform
describ
simul
merscov
posit
npa
prepar
ad
serial
dilut
ml
merscov
two
differ
npa
ml
ml
merscov
addit
npa
neg
mention
respiratori
virus
elisa
perform
describ
use
npa
sampl
fulllength
np
gene
merscov
clone
express
e
coli
strain
stretch
six
histidin
residu
n
c
termini
merscovrnp
molecular
weight
kda
purifi
ninta
affin
chromatographi
use
immun
balbc
mice
western
blot
show
mous
antimerscovrnp
immun
sera
good
reactiv
merscov
merscovrnp
indic
express
merscovrnp
similar
antigen
nativ
np
merscov
figur
control
mous
antimerscovrnp
immun
sera
react
influenza
viru
strain
figur
high
elisa
titer
mous
antimerscovrnp
immun
sera
confirm
merscovrnp
good
immunogen
balbc
mice
indic
merscovrnp
use
gener
antimerscovrnp
mab
figur
total
mab
gener
merscovrnp
elisa
twelv
confirm
merscovrnpspecif
mab
elisa
use
merscovrnp
well
figur
clone
express
purif
procedur
describ
merscovrnp
data
shown
mab
show
differ
degre
crossreact
among
three
rnp
protein
suggest
np
differ
cov
might
common
epitop
establish
captur
elisa
merscov
np
detect
two
antimerscovrnpspecif
mab
select
mab
coat
onto
micropl
mab
conjug
hrp
elisa
show
high
sensit
detect
limit
merscovrnp
less
ngml
high
specif
detect
figur
high
sensit
confirm
detect
limit
inactiv
viral
lysat
merscov
cultur
high
specif
confirm
detect
inactiv
viral
lysat
two
hcov
two
influenza
viru
strain
one
influenza
b
viru
strain
one
rsv
strain
figur
mean
valu
human
npa
neg
influenza
b
c
virus
adenoviru
rsv
parainfluenza
virus
human
rhinovirus
human
metapneumoviru
merscov
use
cutoff
npa
posit
variou
viral
respiratori
tract
infect
neg
mean
od
sd
figur
therefor
specif
captur
elisa
npa
two
simul
merscov
posit
npa
serial
dilut
ml
live
merscov
ad
sampl
ml
show
posit
result
figur
addit
npa
ml
ml
live
merscov
ad
show
posit
result
figur
report
develop
mabsbas
antigen
captur
elisa
merscovnp
previou
experi
sarscov
shown
sarscovnp
detect
sar
patient
highli
feasibl
use
antigen
captur
elisabas
sinc
np
also
import
highli
immunogen
abundantli
express
structur
protein
merscov
detect
use
similar
principl
also
feasibl
np
protein
prefer
target
protein
np
protein
present
much
higher
amount
protein
studi
use
hyperimmun
sera
obtain
mice
immun
three
dose
merscovrnp
confirm
merscovnp
abundantli
present
inactiv
merscov
cell
cultur
figur
antigen
captur
elisa
design
use
two
differ
mab
high
specif
antibodi
titer
merscovrnp
figur
half
mab
gener
show
differ
degre
crossreact
andor
suggest
possibl
common
epitop
across
differ
cov
mabsbas
elisa
much
specif
polyclon
antibodiesbas
elisa
use
hyperimmun
sera
gener
two
differ
kind
anim
immun
merscovrnp
addit
high
specif
also
observ
merscovrnp
merscovnp
detect
present
assay
protein
inactiv
viral
concentr
low
ngml
respect
figur
evalu
diagnost
test
use
control
simul
clinic
specimen
show
present
elisa
highli
sensit
specif
merscov
use
npa
posit
variou
respiratori
virus
show
antigen
captur
elisa
highli
specif
importantli
npa
posit
four
human
cov
show
low
od
valu
present
merscov
antigen
detect
assay
merscovnp
share
amino
acid
ident
alphacov
alphacov
betacov
betacov
respect
import
mer
case
hong
kong
far
access
mer
patient
sampl
use
simul
npa
spike
live
merscov
evalu
sinc
assay
abl
detect
simul
npa
sampl
viral
load
low
ml
live
merscov
diagnost
tool
suitabl
earli
diagnosi
mer
sinc
viral
load
npa
patient
acut
infect
usual
around
present
merscovnp
captur
elisa
potenti
use
detect
merscov
dromedari
camel
sampl
screen
anim
specimen
merscov
although
ancestr
origin
merscov
believ
dromedari
like
immedi
anim
reservoir
transmiss
merscov
human
high
titer
antibodi
merscov
detect
adult
dromedari
middl
merscov
also
found
nasal
sampl
small
proport
merscov
also
detect
nasal
sampl
dromedari
viral
load
around
present
elisa
readili
use
detect
merscov
dromedari
prevent
mer
infect
well
case
mer
outbreak
may
necessari
screen
isol
dromedari
activ
shed
merscov
sinc
present
elisa
captur
merscovnp
antigen
abl
detect
merscov
regardless
sourc
specimen
extrem
use
assess
viral
shed
pattern
dromedari
well
search
anim
sourc
merscov
antigen
detect
elisa
suitabl
clinic
use
field
studi
middl
east
case
mer
occur
far
patient
mer
either
resid
recent
travel
histori
middl
east
therefor
mer
diagnost
test
develop
abl
use
clinic
microbiolog
laboratori
middl
east
anim
reservoir
infect
dromedari
also
live
middl
east
well
north
africa
compar
quantit
realtim
rtpcr
consum
cost
present
antigen
captur
elisa
lower
also
requir
expertis
molecular
technolog
expens
setup
molecular
studi
may
present
clinic
microbiolog
laboratori
middl
east
exampl
million
peopl
includ
two
million
pilgrim
visit
mecca
saudi
arabia
everi
year
particular
high
concentr
visitor
expect
hajj
period
userfriendli
laboratori
test
would
necessari
handl
larg
number
expos
peopl
well
potenti
outbreak
mass
gather
therefor
present
elisa
like
suitabl
quantit
realtim
rtpcr
use
laboratori
middl
east
north
africa
resourc
expertis
could
limit
anim
test
would
extrem
use
track
transmiss
pattern
merscov
among
dromedari
farm
well
across
differ
countri
refin
test
develop
rapid
antigen
detect
kit
onthespot
diagnosi
warrant
